# Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

> **NCT00148798** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 1861 (actual)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** cetuximab + cisplatin + vinorelbine
- **DRUG:** cisplatin + vinorelbine

## Key facts

- **NCT ID:** NCT00148798
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-07
- **Final completion:** 2012-05
- **Target enrollment:** 1861 (ACTUAL)
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148798, "Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00148798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*